Ansuvimab (also known as MEDI-8897) is an investigational monoclonal antibody (mAb) being developed by MedImmune, the global biologics research and development arm of AstraZeneca, for the treatment of moderate to severe COVID-19. The mAb targets a viral protein called the spike protein, which is found on the surface of the SARS-CoV-2 virus and is essential for it to attach to and enter human cells. By targeting this protein, Ansuvimab has the potential to block the virus from entering human cells and thus prevent infection. The mAb is being studied in combination with other mAbs in phase 2/3 clinical trials, and the results are expected to be available soon.
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication used for the treatment of Zaire ebolavirus (Ebola virus) infection in adults and children, including newborns born to mothers with Ebola. Here's a detailed description of Ansuvimab:
Function:
- Ansuvimab works by neutralizing the Ebola virus. It is a human IgG1 monoclonal antibody specifically designed to bind to the glycoprotein on the surface of the Ebola virus. This glycoprotein is essential for the virus to enter and infect host cells.
- By binding to this specific site, Ansuvimab prevents the virus from attaching to and infecting healthy cells. This effectively neutralizes the virus and helps the body's immune system fight off the infection.
Administration:
- Ansuvimab is administered by intravenous infusion (drip) into a vein, typically over a period of 60 minutes.
- The recommended dosage is a single infusion, but it may be repeated in some cases based on the individual's response to treatment and the severity of the infection.
Benefits:
- Ansuvimab has been shown to be effective in treating Ebola virus infection. Clinical trials have demonstrated a significant reduction in mortality rates among patients treated with Ansuvimab compared to those who received other treatments or no treatment.
Important Considerations:
- Not a cure: Ansuvimab is not a cure for Ebola virus infection; it is a treatment that helps the body fight off the infection.
- Potential side effects: As with any medication, Ansuvimab can cause side effects, although they are generally mild and well- tolerated. Common side effects may include headache, fever, chills, fatigue, nausea, and vomiting.
- Limited availability: Ansuvimab is a relatively new medication and may not be readily available in all healthcare settings.